デフォルト表紙
市場調査レポート
商品コード
1469105

抗肥満薬市場:2024-2034年

Anti-obesity Drugs Market Report 2024-2034

出版日: | 発行: Visiongain Reports Ltd. | ページ情報: 英文 310 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: GBPを日本円(税抜)に換算
本日の銀行送金レート: 1GBP=205.16円

ご注意:
Single UserとTeamライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

抗肥満薬市場:2024-2034年
出版日: 2024年04月12日
発行: Visiongain Reports Ltd.
ページ情報: 英文 310 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の抗肥満薬の市場規模は、2034年にかけてCAGR 21.2%で成長すると予測されています。

肥満の増加:

過去数十年の間に、遺伝的、環境的、社会経済的、文化的要因が重なり、肥満率はあらゆる年齢層と人口層で劇的に上昇しました。The World Obesity Federationは、2020年までに世界で約7億7,000万人の成人が肥満の影響を受けていると推定しており、この数字は2030年までに10億人を超えると予測されています。食習慣の変化、座りがちなライフスタイル、都市化、グローバル化により、不健康な食事パターンが広まり、身体活動レベルが低下し、過剰な体重増加や肥満に関連した健康合併症を引き起こしています。さらに、肥満は単独の健康状態であるだけでなく、2型糖尿病、心血管疾患、特定の癌、筋骨格系障害など、多くの慢性疾患の主要な危険因子でもあり、ポピュレーションヘルスへの影響をさらに悪化させています。肥満がもたらす結果は、個人の健康上の結果にとどまらず、ヘルスケアコストの増加、生産性の低下、生活の質の低下など、社会的・経済的負担にまで及んでいます。肥満の多面的な要因に対処するためには、健康的なライフスタイルを促進し、栄養価の高い食品へのアクセスを改善し、身体活動を支援する環境を整えることを目的とした政策的介入、地域社会に根ざした取り組み、教育キャンペーン、ヘルスケア戦略を含む包括的かつ多部門的なアプローチが必要です。肥満の根本原因に取り組み、効果的な予防・治療対策を実施することで、利害関係者は肥満の蔓延を緩和し、世界の健康と福祉に及ぼす遠大な影響を軽減することができます。

医療支出の増加:

肥満率が世界的に上昇を続ける中、医療制度はこの傾向への対策を目的とした介入策にますます資源を割り当てています。この支出の増加は、より効果的な抗肥満薬を新たに開発するためのR&D、肥満管理戦略に関する医療従事者の教育・訓練、患者へのアウトリーチや支援プログラムなど、さまざまな側面に及んでいます。さらに、糖尿病、心血管疾患、特定の癌など、肥満に関連する健康合併症の経済的負担は、こうした下流の健康コストを軽減するための予防・治療対策への投資の必要性をさらに強調しています。さらに、医療制度が予防的介入と慢性疾患管理を優先するバリューベースのケアモデルへと移行するにつれ、包括的な肥満治療計画における薬物療法の役割が重視されるようになってきています。抗肥満薬の初期費用は多額に思えるかもしれませんが、健康の改善や肥満関連合併症に関連する医療費の削減という長期的な潜在的利益はコストを上回ることが多いです。全体として、抗肥満薬市場における医療支出の増加は、差し迫った公衆衛生上の問題への戦略的投資を反映したものであり、この傾向がもたらす広範な社会的・経済的影響を緩和するために、医療予算の中で肥満管理を優先することの重要性を強調するものです。

当レポートでは、世界の抗肥満薬の市場を調査し、市場概要、市場成長への影響因子および市場機会の分析、市場規模の推移・予測、各種区分・地域別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 レポート概要

第2章 エグゼクティブサマリー

第3章 市場概要

  • 主な調査結果
  • 市場力学
    • 市場牽引要因
    • 市場抑制要因
    • 市場機会
  • 抗肥満薬の分析
  • COVID-19の影響分析
  • ポーターのファイブフォース分析
  • PEST分析

第4章 抗肥満薬市場の分析:薬剤タイプ別

  • 主要調査結果
  • 市場魅力度指数
  • 市場規模の推移・予測
  • 処方箋
  • OTC
    • 市場規模の推移・予測:地域別
    • 市場シェア:地域別

第5章 抗肥満薬市場の分析:作用機序別

  • 主要調査結果
  • 市場魅力度指数
  • 市場規模の推移・予測
  • GLP-1作動薬
  • GIPR拮抗薬
  • アミリン受容体作動薬
  • リパーゼ阻害剤
  • SNRI
  • その他
    • 市場規模の推移・予測:地域別
    • 市場シェア:地域別

第6章 抗肥満薬市場の分析:投与経路別

  • 主要調査結果
  • 市場魅力度指数
  • 市場規模の推移・予測
  • 経口
  • 静脈内
  • 皮下
    • 市場規模の推移・予測:地域別
    • 市場シェア:地域別

第7章 抗肥満薬市場の分析:流通チャネル別

  • 主要調査結果
  • 市場魅力度指数
  • 市場規模の推移・予測
  • 病院薬局
  • 小売薬局
  • オンライン薬局
    • 市場規模の推移・予測:地域別
    • 市場シェア:地域別

第8章 抗肥満薬市場の分析:地域別

  • 主要調査結果
  • 市場規模の推移・予測

第9章 北米の抗肥満薬市場の分析

第10章 欧州の抗肥満薬市場の分析

第11章 アジア太平洋の抗肥満薬市場の分析

第12章 ラテンアメリカの抗肥満薬市場の分析

第13章 中東・アフリカの抗肥満薬市場の分析

第14章 企業プロファイル

  • 競合情勢
  • 戦略的展望
  • Arena Pharmaceuticals Ltd.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Carmot Therapeutics, Inc.
  • CHEPLAPHARM Arzneimittel GmbH
  • CohBar, Inc.
  • Curaxx Pharmaceuticals LLC
  • Eisai Co., Ltd.
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Hanmi Pharm Co., Ltd.
  • Merck &Co., Inc.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Rhythm Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • VIVUS LLC
  • Zydus Lifesciences

第15章 総論・提言

  • Visiongainによる総論
  • 推奨事項
図表

List of Tables

  • Table 1 Anti-obesity Drugs Market Snapshot, 2024 & 2034 (US$ Million, CAGR %)
  • Table 2 Anti-obesity Drugs Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%): "V" Shaped Recovery
  • Table 3 Anti-obesity Drugs Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%): "U" Shaped Recovery
  • Table 4 Anti-obesity Drugs Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%): "W" Shaped Recovery
  • Table 5 Anti-obesity Drugs Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%): "L" Shaped Recovery
  • Table 6 Anti-obesity Drugs Market Drug Type, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 7 Prescription Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 8 OTC Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 9 Anti-obesity Drugs Market by Mechanism of Action, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 10 GLP-1 Agonists Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 11 GIPR Antagonists Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 12 Amylin Receptor Agonist Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 13 Lipase Inhibitors Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 14 SNRI's Agonists Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 15 Others Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 16 Anti-obesity Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 17 Oral Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 18 Intravenous Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 19 Subcutaneous Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 20 Anti-obesity Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 21 Hospital Pharmacies Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 22 Retail Pharmacies Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 23 Online Pharmacies Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 24 Anti-obesity Drugs Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 25 North America Anti-obesity Drugs Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 26 North America Anti-obesity Drugs Market Drug Type, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 27 North America Anti-obesity Drugs Market Mechanism of Action, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 28 North America Anti-obesity Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 29 North America Anti-obesity Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 30 U.S. Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 31 Canada Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 32 Europe Anti-obesity Drugs Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 33 Europe Anti-obesity Drugs Market Drug Type, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 34 Europe Anti-obesity Drugs Market Mechanism of Action, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 35 Europe Anti-obesity Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 36 Europe Anti-obesity Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 37 Germany Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 38 France Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 39 UK Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 40 Italy Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 41 Spain Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 42 Russia Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 43 Poland Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 44 Belgium Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 45 Rest of Europe Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 46 Asia Pacific Anti-obesity Drugs Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 47 Asia Pacific Anti-obesity Drugs Market Drug Type, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 48 Asia Pacific Anti-obesity Drugs Market Mechanism of Action, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 49 Asia Pacific Anti-obesity Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 50 Asia Pacific Anti-obesity Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 51 Japan Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 52 China Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 53 India Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 54 Australia Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 55 South Korea Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 56 Singapore Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 57 Taiwan Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 58 Rest of Asia Pacific Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 59 Latin America Anti-obesity Drugs Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 60 Latin America Anti-obesity Drugs Market Drug Type, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 61 Latin America Anti-obesity Drugs Market Mechanism of Action, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 62 Latin America Anti-obesity Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 63 Latin America Anti-obesity Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 64 Brazil Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 65 Mexico Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 66 Argentina Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 67 Colombia Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 68 Rest of Latin America Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 69 MEA Anti-obesity Drugs Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 70 MEA Anti-obesity Drugs Market Drug Type, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 71 MEA Anti-obesity Drugs Market Mechanism of Action, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 72 MEA Anti-obesity Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 73 MEA Anti-obesity Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 74 GCC Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 75 South Africa Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
  • Table 76 Rest of MEA Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
  • Table 77 Strategic Outlook
  • Table 78 Arena Pharmaceuticals Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 79 Arena Pharmaceuticals Ltd.: Product Benchmarking
  • Table 80 Arena Pharmaceuticals Ltd.: Strategic Outlook
  • Table 81 Bayer AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 82 Bayer AG: Product Benchmarking
  • Table 83 Bayer AG: Strategic Outlook
  • Table 84 Boehringer Ingelheim International GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 85 Boehringer Ingelheim International GmbH: Product Benchmarking
  • Table 86 Boehringer Ingelheim International GmbH: Strategic Outlook
  • Table 87 Carmot Therapeutics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 88 Carmot Therapeutics, Inc.: Product Benchmarking
  • Table 89 Carmot Therapeutics, Inc.: Strategic Outlook
  • Table 90 CHEPLAPHARM Arzneimittel GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 91 CHEPLAPHARM Arzneimittel GmbH.: Product Benchmarking
  • Table 92 CHEPLAPHARM Arzneimittel GmbH.: Strategic Outlook
  • Table 93 CohBar, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 94 CohBar, Inc.: Product Benchmarking
  • Table 95 CohBar, Inc.: Strategic Outlook
  • Table 96 Curaxx Pharmaceuticals LLC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 97 Curaxx Pharmaceuticals LLC: Product Benchmarking
  • Table 98 Curaxx Pharmaceuticals LLC: Strategic Outlook
  • Table 99 Eisai Co. Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 100 Eisai Co. Ltd: Product Benchmarking
  • Table 101 Eisai Co. Ltd: Strategic Outlook
  • Table 102 Eli Lilly and Co: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 103 Eli Lilly and Co: Product Benchmarking
  • Table 104 Eli Lilly and Co: Strategic Outlook
  • Table 105 F. Hoffmann-La Roche Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 106 F. Hoffmann-La Roche Ltd.: Product Benchmarking
  • Table 107 F. Hoffmann-La Roche Ltd: Strategic Outlook
  • Table 108 GlaxoSmithKline Plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 109 GlaxoSmithKline Plc: Product Benchmarking
  • Table 110 GlaxoSmithKline Plc: Strategic Outlook
  • Table 111 Hanmi Pharm Co., Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 112 Hanmi Pharm Co., Ltd.: Product Benchmarking
  • Table 113 Hanmi Pharm Co., Ltd.: Strategic Outlook
  • Table 114 Merck & Co., Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 115 Merck & Co., Inc.: Product Benchmarking
  • Table 116 Merck & Co., Inc.: Strategic Outlook
  • Table 117 Novo Nordisk A/S: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 118 Novo Nordisk A/S: Product Benchmarking
  • Table 119 Novo Nordisk A/S: Strategic Outlook
  • Table 120 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 121 Pfizer Inc.: Product Benchmarking
  • Table 122 Pfizer Inc.: Strategic Outlook
  • Table 123 Rhythm Pharmaceuticals, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 124 Rhythm Pharmaceuticals, Inc.: Product Benchmarking
  • Table 125 Rhythm Pharmaceuticals, Inc.: Strategic Outlook
  • Table 126 Takeda Pharmaceutical Company Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 127 Takeda Pharmaceutical Company Limited: Product Benchmarking
  • Table 128 Takeda Pharmaceutical Company Limited: Strategic Outlook
  • Table 129 VIVUS LLC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 130 VIVUS LLC: Product Benchmarking
  • Table 131 VIVUS LLC: Strategic Outlook
  • Table 132 Zydus Lifesciences: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 133 Zydus Lifesciences: Product Benchmarking
  • Table 134 Zydus Lifesciences: Strategic Outlook

List of Figures

  • Figure 1 Anti-obesity Drugs Market Segmentation
  • Figure 2 Anti-obesity Drugs Market by Route of Administration: Market Attractiveness Index
  • Figure 3 Anti-obesity Drugs Market by Distribution Channel: Market Attractiveness Index
  • Figure 4 Anti-obesity Drugs Mechanism of Action: Market Attractiveness Index
  • Figure 5 Anti-obesity Drugs Market by Drug Type: Market Attractiveness Index
  • Figure 6 Anti-obesity Drugs Market Attractiveness Index by Region
  • Figure 7 Anti-obesity Drugs Market: Market Dynamics
  • Figure 8 Top 10 Most Obese Countries in the World
  • Figure 9 Prevalence of Obesity in Different Regions
  • Figure 10 Top Anti-obesity Products by Revenue, 2022
  • Figure 11 Anti-obesity Product Pipeline Analysis by Phase
  • Figure 12 Anti-obesity Products, New Product Launches
  • Figure 13 Anti-obesity Drugs Market by Region, 2024-2034 (US$ Million, AGR %): "V" Shaped Recovery
  • Figure 14 Anti-obesity Drugs Market by Region, 2024-2034 (US$ Million, AGR %): "U" Shaped Recovery
  • Figure 15 Anti-obesity Drugs Market by Region, 2024-2034 (US$ Million, AGR %): "W" Shaped Recovery
  • Figure 16 Anti-obesity Drugs Market by Region, 2024-2034 (US$ Million, AGR %): "L" Shaped Recovery
  • Figure 17 Anti-obesity Drugs Market: Porter's Five Forces Analysis
  • Figure 18 Anti-obesity Drugs Market: PEST Analysis
  • Figure 19 Anti-obesity Drugs Market by Drug Type: Market Attractiveness Index
  • Figure 20 Anti-obesity Drugs Market Forecast by Drug Type, 2024-2034 (US$ Million, AGR %)
  • Figure 21 Anti-obesity Drugs Market Share Forecast by Drug Type 2024, 2029, 2034 (%)
  • Figure 22 Prescription Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 23 Prescription Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 24 OTC Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 25 OTC Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 26 Anti-obesity Drugs Market by Mechanism of Action: Market Attractiveness Index
  • Figure 27 Anti-obesity Drugs Market Forecast by Mechanism of Action, 2024-2034 (US$ Million, AGR %)
  • Figure 28 Anti-obesity Drugs Market Share Forecast by Mechanism of Action; 2024, 2029, 2034 (%)
  • Figure 29 GLP-1 Agonists Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 30 GLP-1 Agonists Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 31 GIPR Antagonists Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 32 GIPR Antagonists Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 33 Amylin Receptor Agonist Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 34 Amylin Receptor Agonist Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 35 Lipase Inhibitors Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 36 Lipase Inhibitors Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 37 SNRI's Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 38 SNRI's Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 39 Others Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 40 Others Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 41 Anti-obesity Drugs Market by Route of Administration: Market Attractiveness Index
  • Figure 42 Anti-obesity Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)
  • Figure 43 Anti-obesity Drugs Market Share Forecast by Route of Administration, 2024, 2029, 2034 (%)
  • Figure 44 Oral Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 45 Oral Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 46 Intravenous Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 47 Intravenous Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 48 Subcutaneous Stimulator Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 49 Subcutaneous Stimulator Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 50 Anti-obesity Drugs Market by Distribution Channel: Market Attractiveness Index
  • Figure 51 Anti-obesity Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
  • Figure 52 Anti-obesity Drugs Market Share Forecast by Route of Administration, 2024, 2029, 2034 (%)
  • Figure 53 Hospital Pharmacies Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 54 Hospital Pharmacies Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 55 Retail Pharmacies Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 56 Retail Pharmacies Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 57 Online Pharmacies Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 58 Online Pharmacies Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 59 Anti-obesity Drugs Market Forecast by Region 2024 and 2034 (Revenue, CAGR %)
  • Figure 60 Anti-obesity Drugs Market Share Forecast by Region 2024, 2029, 2034 (%)
  • Figure 61 Anti-obesity Drugs Market by Region, 2024-2034 (US$ Million, AGR %)
  • Figure 62 North America Anti-obesity Drugs Market Attractiveness Index
  • Figure 63 North America Anti-obesity Drugs Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 64 North America Anti-obesity Drugs Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 65 North America Anti-obesity Drugs Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 66 North America Anti-obesity Drugs Market Forecast by Drugs, 2024-2034 (US$ Million, AGR %)
  • Figure 67 North America Anti-obesity Drugs Market Share Forecast by Drugs, 2024 & 2034 (%)
  • Figure 68 North America Anti-obesity Drugs Market Forecast by Mechanism of Action, 2024-2034 (US$ Million, AGR %)
  • Figure 69 North America Anti-obesity Drugs Market Share Forecast by Mechanism of Action, 2024 & 2034 (%)
  • Figure 70 North America Anti-obesity Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)
  • Figure 71 North America Anti-obesity Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
  • Figure 72 North America Anti-obesity Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
  • Figure 73 North America Anti-obesity Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 74 U.S. Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 75 Canada Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 76 Europe Anti-obesity Drugs Market Attractiveness Index
  • Figure 77 Europe Anti-obesity Drugs Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 78 Europe Anti-obesity Drugs Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 79 Europe Anti-obesity Drugs Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 80 Europe Anti-obesity Drugs Market Forecast by Drugs, 2024-2034 (US$ Million, AGR %)
  • Figure 81 Europe Anti-obesity Drugs Market Share Forecast by Drugs, 2024 & 2034 (%)
  • Figure 82 Europe Anti-obesity Drugs Market Forecast by Mechanism of Action, 2024-2034 (US$ Million, AGR %)
  • Figure 83 Europe Anti-obesity Drugs Market Share Forecast by Mechanism of Action, 2024 & 2034 (%)
  • Figure 84 Europe Anti-obesity Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)
  • Figure 85 Europe Anti-obesity Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
  • Figure 86 Europe Anti-obesity Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
  • Figure 87 Europe Anti-obesity Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 88 Germany Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 89 France Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 90 UK Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 91 Italy Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 92 Spain Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 93 Russia Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 94 Poland Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 95 Belgium Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 96 Rest of Europe Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 97 Asia Pacific Anti-obesity Drugs Market Attractiveness Index
  • Figure 98 Asia Pacific Anti-obesity Drugs Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 99 Asia Pacific Anti-obesity Drugs Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 100 Asia Pacific Anti-obesity Drugs Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 101 Asia Pacific Anti-obesity Drugs Market Forecast by Drugs Type, 2024-2034 (US$ Million, AGR %)
  • Figure 102 Asia Pacific Anti-obesity Drugs Market Share Forecast by Drugs Type, 2024 & 2034 (%)
  • Figure 103 Asia Pacific Anti-obesity Drugs Market Forecast by Mechanism of Action, 2024-2034 (US$ Million, AGR %)
  • Figure 104 Asia Pacific Anti-obesity Drugs Market Share Forecast by Mechanism of Action, 2024 & 2034 (%)
  • Figure 105 Asia Pacific Anti-obesity Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)
  • Figure 106 Asia Pacific Anti-obesity Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
  • Figure 107 Asia Pacific Anti-obesity Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
  • Figure 108 Asia Pacific Anti-obesity Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 109 Japan Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 110 China Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 111 India Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 112 Australia Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 113 South Korea Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 114 Singapore Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 115 Taiwan Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 116 Rest of Asia Pacific Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 117 Latin America Anti-obesity Drugs Market Attractiveness Index
  • Figure 118 Latin America Anti-obesity Drugs Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 119 Latin America Anti-obesity Drugs Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 120 Latin America Anti-obesity Drugs Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 121 Latin America Anti-obesity Drugs Market Forecast by Drugs type, 2024-2034 (US$ Million, AGR %)
  • Figure 122 Latin America Anti-obesity Drugs Market Share Forecast by Drug type, 2024 & 2034 (%)
  • Figure 123 Latin America Anti-obesity Drugs Market Forecast by Mechanism of Action, 2024-2034 (US$ Million, AGR %)
  • Figure 124 Latin America Anti-obesity Drugs Market Share Forecast by Mechanism of Action, 2024 & 2034 (%)
  • Figure 125 Latin America Anti-obesity Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)
  • Figure 126 Latin America Anti-obesity Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
  • Figure 127 Latin America Anti-obesity Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
  • Figure 128 Latin America Anti-obesity Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 129 Brazil Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 130 Mexico Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 131 Argentina Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 132 Colombia Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 133 Rest of Latin America Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 134 MEA Anti-obesity Drugs Market Attractiveness Index
  • Figure 135 MEA Anti-obesity Drugs Market by Region, 2024, 2029 & 2034 (US$ Million)
  • Figure 136 MEA Anti-obesity Drugs Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
  • Figure 137 MEA Anti-obesity Drugs Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 138 MEA Anti-obesity Drugs Market Forecast by Drug Type, 2024-2034 (US$ Million, AGR %)
  • Figure 139 MEA Anti-obesity Drugs Market Share Forecast by Drug Type, 2024 & 2034 (%)
  • Figure 140 MEA Anti-obesity Drugs Market Forecast by Mechanism of Action, 2024-2034 (US$ Million, AGR %)
  • Figure 141 MEA Anti-obesity Drugs Market Share Forecast by Mechanism of Action, 2024 & 2034 (%)
  • Figure 142 MEA Anti-obesity Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Million, AGR %)
  • Figure 143 MEA Anti-obesity Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
  • Figure 144 MEA Anti-obesity Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
  • Figure 145 MEA Anti-obesity Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 146 GCC Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 147 South Africa Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 148 Rest of MEA Anti-obesity Drugs Market Forecast, 2024-2034 (US$ Million, AGR %)
  • Figure 149 Anti-obesity Market Company Share, 2022
  • Figure 150 Arena Pharmaceuticals Ltd.: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 151 Arena Pharmaceuticals Ltd.: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 152 Arena Pharmaceuticals Ltd.: Regional Market Shares, 2022
  • Figure 153 Bayer AG: Net Revenue, 2017-2023 (US$ Million, AGR%)
  • Figure 154 Bayer AG : R&D, 2017-2023 (US$ Million, AGR%)
  • Figure 155 Bayer AG: Regional Market Shares, 2023
  • Figure 156 Boehringer Ingelheim International GmbH: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 157 Boehringer Ingelheim International GmbH: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 158 Boehringer Ingelheim International GmbH: Regional Market Shares, 2022
  • Figure 159 Eisai Co. Ltd: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 160 Eisai Co. Ltd: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 161 Eisai Co. Ltd: Regional Market Shares, 2022
  • Figure 162 Eli Lilly and Co: Net Revenue, 2017-2023 (US$ Million, AGR%)
  • Figure 163 Eli Lilly and Co: R&D, 2017-2023 (US$ Million, AGR%)
  • Figure 164 Eli Lilly and Co: Regional Market Shares, 2023
  • Figure 165 F. Hoffmann-La Roche Ltd.: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 166 F. Hoffmann-La Roche Ltd.: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 167 GlaxoSmithKline Plc: Net Revenue, 2017-2023 (US$ Million, AGR%)
  • Figure 168 GlaxoSmithKline Plc: R&D, 2017-2023 (US$ Million, AGR%)
  • Figure 169 GlaxoSmithKline Plc: Regional Market Shares, 2023
  • Figure 170 Hanmi Pharm Co., Ltd.: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 171 Merck & Co., Inc.: Net Revenue, 2017-2023 (US$ Million, AGR%)
  • Figure 172 Merck & Co., Inc.: R&D, 2017-2023 (US$ Million, AGR%)
  • Figure 173 Merck & Co., Inc.: Regional Market Shares, 2023
  • Figure 174 Novo Nordisk A/S: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 175 Novo Nordisk A/S: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 176 Novo Nordisk A/S: Regional Market Shares, 2022
  • Figure 177 Pfizer Inc.: Net Revenue, 2017-2023 (US$ Million, AGR%)
  • Figure 178 Pfizer Inc.: R&D, 2017-2023 (US$ Million, AGR%)
  • Figure 179 Pfizer Inc. Regional Market Shares, 2022
  • Figure 180 Rhythm Pharmaceuticals, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 181 Rhythm Pharmaceuticals, Inc.: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 182 Rhythm Pharmaceuticals, Inc. Regional Market Shares, 2022
  • Figure 183 Takeda Pharmaceutical Company Limited: Net Revenue, 2017-2023 (US$ Million, AGR%)
  • Figure 184 Takeda Pharmaceutical Company Limited: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 185 Takeda Pharmaceutical Company Limited: Regional Market Shares, 2023
  • Figure 186 VIVUS LLC: Net Revenue, 2017-2023 (US$ Million, AGR%)
  • Figure 187 VIVUS LLC: R&D, 2017-2019 (US$ Million, AGR%)
  • Figure 188 VIVUS LLC: Regional Market Shares, 2023
  • Figure 189 Zydus Lifesciences: Net Revenue, 2017-2023 (US$ Million, AGR%)
  • Figure 190 Zydus Lifesciences: R&D, 2017-2023 (US$ Million, AGR%)
  • Figure 191 Zydus Lifesciences: Regional Market Shares, 2023
目次
Product Code: PHA1327

The global Anti-obesity Drugs market is estimated to grow at a CAGR of 21.2% by 2034

The Anti-obesity Drugs Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Increased Prevalence of Obesity

Over the past few decades, obesity rates have risen dramatically across all age groups and demographics, fuelled by a combination of genetic, environmental, socioeconomic, and cultural factors. The World Obesity Federation estimated that by 2020 around 770 million adults globally were affected by obesity, and that figure is anticipated to exceed one billion by 2030. Changes in dietary habits, sedentary lifestyles, urbanization, and globalization have contributed to the widespread adoption of unhealthy eating patterns and reduced physical activity levels, leading to excess weight gain and obesity-related health complications. Moreover, obesity is not only a standalone health condition but also a major risk factor for numerous chronic diseases, including type 2 diabetes, cardiovascular diseases, certain cancers, and musculoskeletal disorders, further exacerbating its impact on population health. The consequences of obesity extend beyond individual health outcomes to encompass societal and economic burdens, including increased healthcare costs, lost productivity, and diminished quality of life. Addressing the multifaceted drivers of obesity requires a comprehensive and multi-sectoral approach that encompasses policy interventions, community-based initiatives, education campaigns, and healthcare strategies aimed at promoting healthy lifestyles, improving access to nutritious foods, and creating supportive environments for physical activity. By tackling the root causes of obesity and implementing effective prevention and treatment measures, stakeholders can mitigate the escalating obesity epidemic and mitigate its far-reaching consequences on global health and well-being.

Rising Healthcare Expenditure

As obesity rates continue to climb globally, healthcare systems are increasingly allocating resources towards interventions aimed at combating this epidemic. This heightened expenditure encompasses various aspects, including research and development efforts to innovate new and more effective anti-obesity drugs, healthcare provider education and training on obesity management strategies, as well as patient outreach and support programs. Additionally, the economic burden of obesity-related health complications, such as diabetes, cardiovascular diseases, and certain cancers, further underscores the necessity of investing in preventive and therapeutic measures to mitigate these downstream health costs. Furthermore, as healthcare systems transition towards value-based care models that prioritize preventive interventions and chronic disease management, there is a growing emphasis on the role of pharmacotherapy in comprehensive obesity treatment plans. While the upfront costs of anti-obesity drugs may seem significant, they are often outweighed by the potential long-term benefits of improved health outcomes and reduced healthcare expenditures associated with obesity-related comorbidities. Overall, the rising healthcare expenditure in the anti-obesity drugs market reflects a strategic investment in addressing a pressing public health issue and underscores the importance of prioritizing obesity management within healthcare budgets to mitigate the broader societal and economic impacts of this epidemic.

What Questions Should You Ask before Buying a Market Research Report?

How is the Anti-obesity Drugs Market evolving?

What is driving and restraining the Anti-obesity Drugs Market?

How will each Anti-obesity Drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?

How will the market shares for each Anti-obesity Drugs submarket develop from 2024 to 2034?

What will be the main driver for the overall market from 2024 to 2034?

Will leading Anti-obesity Drugs Markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?

How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?

Who are the leading players and what are their prospects over the forecast period?

What are the Anti-obesity Drugs projects for these leading companies?

How will the industry evolve during the period between 2024 and 2034? What are the implications of Anti-obesity Drugs projects taking place now and over the next 10 years?

Is there a greater need for product commercialisation to further scale the Anti-obesity Drugs Market?

Where is the Anti-obesity Drugs Market heading and how can you ensure you are at the forefront of the market?

What are the best investment options for new product and service lines?

What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Anti-obesity Drugs Market today, and over the next 10 years:

Our 310-page report provides 134 tables and 191 charts/graphs exclusively to you.

The report highlights key lucrative areas in the industry so you can target them - NOW.

It contains in-depth analysis of global, regional and national sales and growth.

It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Anti-obesity Drugs Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.

You will find original analyses, with business outlooks and developments.

Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising anti-obesity drugs prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, "V", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report

Drug Type

Prescription

OTC

Mechanism of Action

Glucagon like Peptide GLP-1 Agonists

Gastric inhibitory Polypeptide Receptor (GIPR) Antagonist

Amylin Receptor Agonist

Lipase Inhibitors

Serotonin and Norepinephrine Reuptake Inhibitor (SNRI)

Others

Route of Administration

Oral

Intravenous

Subcutaneous

Distribution channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 25 leading national markets:

North America

U.S.

Canada

Europe

Germany

UK

France

Spain

Italy

Poland

Belgium

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Singapore

Taiwan

Rest of Asia Pacific

Latin America

Brazil

Mexico

Argentina

Rest of Latin America

MEA

GCC

South Africa

Rest of MEA

The report also includes profiles and for some of the leading companies in the Anti-obesity Drugs Market, 2024 to 2034, with a focus on this segment of these companies' operations.

Leading companies profiled in the report

Arena Pharmaceuticals Ltd.

Bayer AG

Boehringer Ingelheim International GmbH

Carmot Therapeutics, Inc.

CHEPLAPHARM Arzneimittel GmbH

CohBar, Inc.

Curaxx Pharmaceuticals LLC

Eisai Co., Ltd.

Eli Lilly and Co

F. Hoffmann-La Roche Ltd

GlaxoSmithKline Plc

Hanmi Pharm Co., Ltd.

Merck & Co., Inc.

Novo Nordisk A/S

Pfizer Inc.

Rhythm Pharmaceuticals, Inc.

Takeda Pharmaceutical Company Limited

VIVUS LLC

Zydus Lifesciences

Overall world revenue for Anti-obesity Drugs Market, 2024 to 2034 in terms of value the market will surpass US$78,000 million in 2034, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Anti-obesity Drugs Market, 2024 to 2034 report help you?

In summary, our 310-page report provides you with the following knowledge:

Revenue forecasts to 2034 for Anti-obesity Drugs Market 2024 to 2034, with forecasts for drug type, Mechanism of action, route of administration, and distribution channel, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.

Revenue forecasts to 2034 for five regional and 27 key national markets - See forecasts for the Anti-obesity Drugs Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

Prospects for established firms and those seeking to enter the market - including company profiles for 17 of the major companies involved in the Anti-obesity Drugs Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Anti-obesity Drugs Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Anti-obesity Drugs Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
    • 3.2.1 Market Driving Factors
      • 3.2.1.1 Increasing Prevalence of Obesity
      • 3.2.1.2 Growing Awareness of Health Risks Associated with Obesity
      • 3.2.1.3 Technological Advancements
      • 3.2.1.4 Favourable Government Policies to Address Obesity Epidemic
    • 3.2.2 Market Restraining Factors
      • 3.2.2.1 Adverse Drugs Reactions Associated with Anti-obesity Drugs
      • 3.2.2.2 Adherence to Weight Management Medications
      • 3.2.2.3 Lack of Access to Affordable Anti-obesity Drugs
    • 3.2.3 Market Opportunities
      • 3.2.3.1 Increasing Number of Individuals Grappling with Obesity
      • 3.2.3.2 Automation in Drug Development Technologies
      • 3.2.3.3 Utilization of Digital Platforms to Enhance Patient Engagement
  • 3.3 Anti-obesity Drugs Analysis
    • 3.3.1 Top Anti-obesity Products, by Revenue
    • 3.3.2 Pipeline Analysis by Phase
    • 3.3.3 New Product Launches
  • 3.4 COVID-19 Impact Analysis
  • 3.5 Porter's Five Forces Analysis
    • 3.5.1 Bargaining Power of Suppliers
    • 3.5.2 Bargaining Power of Buyers
    • 3.5.3 Competitive Rivalry
    • 3.5.4 Threat of Substitutes
    • 3.5.5 Threat of New Entrants
  • 3.6 PEST Analysis

4 Anti-obesity Drugs Market Analysis by Drug Type

  • 4.1 Key Findings
  • 4.2 Drug Type Segment: Market Attractiveness Index
  • 4.3 Anti-obesity Drugs Market Size Estimation and Forecast by Type
  • 4.4 Prescription
    • 4.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 4.4.2 Market Share by Region, 2024 & 2034 (%)
  • 4.5 OTC
    • 4.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 4.5.2 Market Share by Region, 2024 & 2034 (%)

5 Anti-obesity Drugs Market Analysis by Mechanism of Action

  • 5.1 Key Findings
  • 5.2 Drug Type Segment: Market Attractiveness Index
  • 5.3 Anti-obesity Drugs Market Size Estimation and Forecast by Mechanism of Action
  • 5.4 GLP-1 Agonists
    • 5.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.4.2 Market Share by Region, 2024 & 2034 (%)
  • 5.5 GIPR Antagonists
    • 5.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.5.2 Market Share by Region, 2024 & 2034 (%)
  • 5.6 Amylin Receptor Agonist
    • 5.6.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.6.2 Market Share by Region, 2024 & 2034 (%)
  • 5.7 Lipase Inhibitors
    • 5.7.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.7.2 Market Share by Region, 2024 & 2034 (%)
  • 5.8 SNRI's
    • 5.8.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.8.2 Market Share by Region, 2024 & 2034 (%)
  • 5.9 Others
    • 5.9.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.9.2 Market Share by Region, 2024 & 2034 (%)

6 Anti-obesity Drugs Market Analysis by Route of Administration

  • 6.1 Key Findings
  • 6.2 Route of Administration Segment: Market Attractiveness Index
  • 6.3 Anti-obesity Drugs Market Size Estimation and Forecast by Route of Administration
  • 6.4 Oral
    • 6.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 6.4.2 Market Share by Region, 2024 & 2034 (%)
  • 6.5 Intravenous
    • 6.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 6.5.2 Market Share by Region, 2024 & 2034 (%)
  • 6.6 Subcutaneous
    • 6.6.1 Market Size by Region, 2024-2034 (US$ Million)
    • 6.6.2 Market Share by Region, 2024 & 2034 (%)

7 Anti-obesity Drugs Market Analysis by Distribution Channel

  • 7.1 Key Findings
  • 7.2 Distribution Channel Segment: Market Attractiveness Index
  • 7.3 Anti-obesity Drugs Market Size Estimation and Forecast by Distribution Channel
  • 7.4 Hospital Pharmacies
    • 7.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 7.4.2 Market Share by Region, 2024 & 2034 (%)
  • 7.5 Retail Pharmacies
    • 7.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 7.5.2 Market Share by Region, 2024 & 2034 (%)
  • 7.6 Online Pharmacies
    • 7.6.1 Market Size by Region, 2024-2034 (US$ Million)
    • 7.6.2 Market Share by Region, 2024 & 2034 (%)

8 Anti-obesity Drugs Market Analysis by Region

  • 8.1 Key Findings
  • 8.2 Regional Market Size Estimation and Forecast

9 North America Anti-obesity Drugs Market Analysis

  • 9.1 Key Findings
  • 9.2 North America Anti-obesity Drugs Market Attractiveness Index
  • 9.3 North America Anti-obesity Drugs Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 9.4 North America Anti-obesity Drugs Market Size Estimation and Forecast by Country
  • 9.5 North America Anti-obesity Drugs Market Size Estimation and Forecast by Drug Type
  • 9.6 North America Anti-obesity Drugs Market Size Estimation and Forecast by Mechanism of Action
  • 9.7 North America Anti-obesity Drugs Market Size Estimation and Forecast by Route of Administration
  • 9.8 North America Anti-obesity Drugs Market Size Estimation and Forecast by Distribution Channel
  • 9.9 U.S. Anti-obesity Drugs Market Analysis
  • 9.10 Canada Anti-obesity Drugs Market Analysis

10 Europe Anti-obesity Drugs Market Analysis

  • 10.1 Key Findings
  • 10.2 Europe Anti-obesity Drugs Market Attractiveness Index
  • 10.3 Europe Anti-obesity Drugs Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 10.4 Europe Anti-obesity Drugs Market Size Estimation and Forecast by Country
  • 10.5 Europe Anti-obesity Drugs Market Size Estimation and Forecast by Drug Type
  • 10.6 Europe Anti-obesity Drugs Market Size Estimation and Forecast by Mechanism of Action
  • 10.7 Europe Anti-obesity Drugs Market Size Estimation and Forecast by Route of Administration
  • 10.8 Europe Anti-obesity Drugs Market Size Estimation and Forecast by Distribution Channel
  • 10.9 Germany Anti-obesity Drugs Market Analysis
  • 10.10 France Anti-obesity Drugs Market Analysis
  • 10.11 UK Anti-obesity Drugs Market Analysis
  • 10.12 Italy Anti-obesity Drugs Market Analysis
  • 10.13 Spain Anti-obesity Drugs Market Analysis
  • 10.14 Russia Anti-obesity Drugs Market Analysis
  • 10.15 Poland Anti-obesity Drugs Market Analysis
  • 10.16 Belgium Anti-obesity Drugs Market Analysis
  • 10.17 Rest of Europe Anti-obesity Drugs Market Analysis

11 Asia Pacific Anti-obesity Drugs Market Analysis

  • 11.1 Key Findings
  • 11.2 Asia Pacific Anti-obesity Drugs Market Attractiveness Index
  • 11.3 Asia Pacific Anti-obesity Drugs Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 11.4 Asia Pacific Anti-obesity Drugs Market Size Estimation and Forecast by Country
  • 11.5 Asia Pacific Anti-obesity Drugs Market Size Estimation and Forecast by Drug Type
  • 11.6 Asia Pacific Anti-obesity Drugs Market Size Estimation and Forecast by Mechanism of Action
  • 11.7 Asia Pacific Anti-obesity Drugs Market Size Estimation and Forecast by Route of Administration
  • 11.8 Asia Pacific Anti-obesity Drugs Market Size Estimation and Forecast by Distribution Channel
  • 11.9 Japan Anti-obesity Drugs Market Analysis
  • 11.10 China Anti-obesity Drugs Market Analysis
  • 11.11 India Anti-obesity Drugs Market Analysis
  • 11.12 Australia Anti-obesity Drugs Market Analysis
  • 11.13 South Korea Anti-obesity Drugs Market Analysis
  • 11.14 Singapore Anti-obesity Drugs Market Analysis
  • 11.15 Taiwan Anti-obesity Drugs Market Analysis
  • 11.16 Rest of Asia Pacific Anti-obesity Drugs Market Analysis

12 Latin America Anti-obesity Drugs Market Analysis

  • 12.1 Key Findings
  • 12.2 Latin America Anti-obesity Drugs Market Attractiveness Index
  • 12.3 Latin America Anti-obesity Drugs Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 12.4 Latin America Anti-obesity Drugs Market Size Estimation and Forecast by Country
  • 12.5 Latin America Anti-obesity Drugs Market Size Estimation and Forecast by Drug Type
  • 12.6 Latin America Anti-obesity Drugs Market Size Estimation and Forecast by Mechanism of Action
  • 12.7 Latin America Anti-obesity Drugs Market Size Estimation and Forecast by Route of Administration
  • 12.8 Latin America Anti-obesity Drugs Market Size Estimation and Forecast by Distribution Channel
  • 12.9 Brazil Anti-obesity Drugs Market Analysis
  • 12.10 Mexico Anti-obesity Drugs Market Analysis
  • 12.11 Argentina Anti-obesity Drugs Market Analysis
  • 12.12 Colombia Anti-obesity Drugs Market Analysis
  • 12.13 Rest of Latin America Anti-obesity Drugs Market Analysis

13 MEA Anti-obesity Drugs Market Analysis

  • 13.1 Key Findings
  • 13.2 MEA Anti-obesity Drugs Market Attractiveness Index
  • 13.3 MEA Anti-obesity Drugs Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 13.4 MEA Anti-obesity Drugs Market Size Estimation and Forecast by Country
  • 13.5 MEA Anti-obesity Drugs Market Size Estimation and Forecast by Drug Type
  • 13.6 MEA Anti-obesity Drugs Market Size Estimation and Forecast by Mechanism of Action
  • 13.7 MEA Anti-obesity Drugs Market Size Estimation and Forecast by Route of Administration
  • 13.8 MEA Anti-obesity Drugs Market Size Estimation and Forecast by Distribution Channel
  • 13.9 GCC Anti-obesity Drugs Market Analysis
  • 13.10 South Africa Anti-obesity Drugs Market Analysis
  • 13.11 Rest of MEA Anti-obesity Drugs Market Analysis

14 Company Profiles

  • 14.1 Competitive Landscape, 2022
  • 14.2 Summary of all Strategic Outlook
  • 14.3 Arena Pharmaceuticals Ltd.
    • 14.3.1 Company Snapshot
    • 14.3.2 Company Overview
    • 14.3.3 Financial Analysis
      • 14.3.3.1 Net Revenue, 2017-2022
      • 14.3.3.2 R&D, 2017-2022
      • 14.3.3.3 Regional Market Shares, 2022
    • 14.3.4 Product Benchmarking
    • 14.3.5 Strategic Outlook
  • 14.4 Bayer AG
    • 14.4.1 Company Snapshot
    • 14.4.2 Company Overview
    • 14.4.3 Financial Analysis
      • 14.4.3.1 Net Revenue, 2017-2023
      • 14.4.3.2 R&D, 2017-2023
      • 14.4.3.3 Regional Market Shares, 2023
    • 14.4.4 Product Benchmarking
    • 14.4.5 Strategic Outlook
  • 14.5 Boehringer Ingelheim International GmbH
    • 14.5.1 Company Snapshot
    • 14.5.2 Company Overview
    • 14.5.3 Financial Analysis
      • 14.5.3.1 Net Revenue, 2017-2022
      • 14.5.3.2 R&D, 2017-2022
      • 14.5.3.3 Regional Market Shares, 2022
    • 14.5.4 Product Benchmarking
    • 14.5.5 Strategic Outlook
  • 14.6 Carmot Therapeutics, Inc.
    • 14.6.1 Company Snapshot
    • 14.6.2 Company Overview
    • 14.6.3 Product Benchmarking
    • 14.6.4 Strategic Outlook
  • 14.7 CHEPLAPHARM Arzneimittel GmbH
    • 14.7.1 Company Snapshot
    • 14.7.2 Company Overview
    • 14.7.3 Product Benchmarking
    • 14.7.4 Strategic Outlook
  • 14.8 CohBar, Inc.
    • 14.8.1 Company Snapshot
    • 14.8.2 Company Overview
    • 14.8.3 Product Benchmarking
    • 14.8.4 Strategic Outlook
  • 14.9 Curaxx Pharmaceuticals LLC
    • 14.9.1 Company Snapshot
    • 14.9.2 Company Overview
    • 14.9.3 Product Benchmarking
    • 14.9.4 Strategic Outlook
  • 14.10 Eisai Co., Ltd.
    • 14.10.1 Company Snapshot
    • 14.10.2 Company Overview
    • 14.10.3 Financial Analysis
      • 14.10.3.1 Net Revenue, 2017-2022
      • 14.10.3.2 R&D, 2017-2022
      • 14.10.3.3 Regional Market Shares, 2022
    • 14.10.4 Product Benchmarking
    • 14.10.5 Strategic Outlook
  • 14.11 Eli Lilly and Co
    • 14.11.1 Company Snapshot
    • 14.11.2 Company Overview
    • 14.11.3 Financial Analysis
      • 14.11.3.1 Net Revenue, 2017-2023
      • 14.11.3.2 R&D, 2017-2023
      • 14.11.3.3 Regional Market Shares, 2023
    • 14.11.4 Product Benchmarking
    • 14.11.5 Strategic Outlook
  • 14.12 F. Hoffmann-La Roche Ltd
    • 14.12.1 Company Snapshot
    • 14.12.2 Company Overview
    • 14.12.3 Financial Analysis
      • 14.12.3.1 Net Revenue, 2017-2022
      • 14.12.3.2 R&D, 2017-2022
    • 14.12.4 Product Benchmarking
    • 14.12.5 Strategic Outlook
  • 14.13 GlaxoSmithKline Plc
    • 14.13.1 Company Snapshot
    • 14.13.2 Company Overview
    • 14.13.3 Financial Analysis
      • 14.13.3.1 Net Revenue, 2017-2023
      • 14.13.3.2 R&D, 2017-2023
      • 14.13.3.3 Regional Market Shares, 2023
    • 14.13.4 Product Benchmarking
    • 14.13.5 Strategic Outlook
  • 14.14 Hanmi Pharm Co., Ltd.
    • 14.14.1 Company Snapshot
    • 14.14.2 Company Overview
    • 14.14.3 Financial Analysis
      • 14.14.3.1 Net Revenue, 2017-2022
    • 14.14.4 Product Benchmarking
    • 14.14.5 Strategic Outlook
  • 14.15 Merck & Co., Inc.
    • 14.15.1 Company Snapshot
    • 14.15.2 Company Overview
    • 14.15.3 Financial Analysis
      • 14.15.3.1 Net Revenue, 2017-2023
      • 14.15.3.2 R&D, 2017-2023
      • 14.15.3.3 Regional Market Shares, 2023
    • 14.15.4 Product Benchmarking
    • 14.15.5 Strategic Outlook
  • 14.16 Novo Nordisk A/S
    • 14.16.1 Company Snapshot
    • 14.16.2 Company Overview
    • 14.16.3 Financial Analysis
      • 14.16.3.1 Net Revenue, 2017-2022
      • 14.16.3.2 R&D, 2017-2022
      • 14.16.3.3 Regional Market Shares, 2022
    • 14.16.4 Product Benchmarking
    • 14.16.5 Strategic Outlook
  • 14.17 Pfizer Inc.
    • 14.17.1 Company Snapshot
    • 14.17.2 Company Overview
    • 14.17.3 Financial Analysis
      • 14.17.3.1 Net Revenue, 2017-2023
      • 14.17.3.2 R&D, 2017-2023
      • 14.17.3.3 Regional Market Shares, 2022
    • 14.17.4 Product Benchmarking
    • 14.17.5 Strategic Outlook
  • 14.18 Rhythm Pharmaceuticals, Inc.
    • 14.18.1 Company Snapshot
    • 14.18.2 Company Overview
    • 14.18.3 Financial Analysis
      • 14.18.3.1 Net Revenue, 2017-2022
      • 14.18.3.2 R&D, 2017-2022
      • 14.18.3.3 Regional Market Shares, 2022
    • 14.18.4 Product Benchmarking
    • 14.18.5 Strategic Outlook
  • 14.19 Takeda Pharmaceutical Company Limited
    • 14.19.1 Company Snapshot
    • 14.19.2 Company Overview
    • 14.19.3 Financial Analysis
      • 14.19.3.1 Net Revenue, 2017-2023
      • 14.19.3.2 R&D, 2017-2023
      • 14.19.3.3 Regional Market Shares, 2023
    • 14.19.4 Product Benchmarking
    • 14.19.5 Strategic Outlook
  • 14.20 VIVUS LLC
    • 14.20.1 Company Snapshot
    • 14.20.2 Company Overview
    • 14.20.3 Financial Analysis
      • 14.20.3.1 Net Revenue, 2017-2023
      • 14.20.3.2 R&D, 2017-2019
      • 14.20.3.3 Regional Market Shares, 2023
    • 14.20.4 Product Benchmarking
    • 14.20.5 Strategic Outlook
  • 14.21 Zydus Lifesciences
    • 14.21.1 Company Snapshot
    • 14.21.2 Company Overview
    • 14.21.3 Financial Analysis
      • 14.21.3.1 Net Revenue, 2017-2023
      • 14.21.3.2 R&D, 2017-2023
      • 14.21.3.3 Regional Market Shares, 2023
    • 14.21.4 Product Benchmarking
    • 14.21.5 Strategic Outlook

15 Conclusion and Recommendations

  • 15.1 Concluding Remarks from Visiongain
  • 15.2 Recommendations for Market Players